Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit
- PMID: 30711330
- DOI: 10.1016/j.eururo.2019.01.026
Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit
Abstract
Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this finding might be attributable to bone loss induced by the concomitantly administered prednisone.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment on
-
Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement.Eur Urol Focus. 2020 Sep 15;6(5):991-998. doi: 10.1016/j.euf.2019.01.014. Epub 2019 Feb 14. Eur Urol Focus. 2020. PMID: 30772357
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
